HORIZON THERAPEUTICS PLC (HZNP) Fundamental Analysis & Valuation
NASDAQ:HZNP • IE00BQPVQZ61
Current stock price
116.3 USD
+0.05 (+0.04%)
At close:
116.34 USD
+0.04 (+0.03%)
After Hours:
This HZNP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HZNP Profitability Analysis
1.1 Basic Checks
- HZNP had positive earnings in the past year.
- HZNP had a positive operating cash flow in the past year.
1.2 Ratios
- HZNP has a better Return On Assets (4.71%) than 95.21% of its industry peers.
- HZNP has a better Return On Equity (8.25%) than 95.38% of its industry peers.
- HZNP's Return On Invested Capital of 5.35% is amongst the best of the industry. HZNP outperforms 95.87% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for HZNP is significantly below the industry average of 27.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROIC | 5.35% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
1.3 Margins
- HZNP has a better Profit Margin (12.02%) than 96.04% of its industry peers.
- HZNP's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 15.58%, HZNP belongs to the best of the industry, outperforming 96.53% of the companies in the same industry.
- In the last couple of years the Operating Margin of HZNP has grown nicely.
- Looking at the Gross Margin, with a value of 75.21%, HZNP belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.
- In the last couple of years the Gross Margin of HZNP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% |
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
2. HZNP Health Analysis
2.1 Basic Checks
- HZNP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for HZNP remains at a similar level compared to 1 year ago.
- Compared to 1 year ago, HZNP has an improved debt to assets ratio.
2.2 Solvency
- HZNP has an Altman-Z score of 5.10. This indicates that HZNP is financially healthy and has little risk of bankruptcy at the moment.
- HZNP has a better Altman-Z score (5.10) than 81.35% of its industry peers.
- The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
- HZNP's Debt to FCF ratio of 2.67 is amongst the best of the industry. HZNP outperforms 95.54% of its industry peers.
- A Debt/Equity ratio of 0.48 indicates that HZNP is not too dependend on debt financing.
- HZNP's Debt to Equity ratio of 0.48 is on the low side compared to the rest of the industry. HZNP is outperformed by 74.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Altman-Z | 5.1 |
ROIC/WACC0.75
WACC7.16%
2.3 Liquidity
- HZNP has a Current Ratio of 4.27. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
- HZNP's Current ratio of 4.27 is in line compared to the rest of the industry. HZNP outperforms 41.58% of its industry peers.
- HZNP has a Quick Ratio of 4.09. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 4.09, HZNP perfoms like the industry average, outperforming 40.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 |
3. HZNP Growth Analysis
3.1 Past
- The earnings per share for HZNP have decreased strongly by -19.39% in the last year.
- The Earnings Per Share has been growing by 33.01% on average over the past years. This is a very strong growth
- Looking at the last year, HZNP shows a decrease in Revenue. The Revenue has decreased by -4.42% in the last year.
- The Revenue has been growing by 28.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
3.2 Future
- HZNP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.
- The Revenue is expected to grow by 9.94% on average over the next years. This is quite good.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. HZNP Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.90, HZNP can be considered very expensive at the moment.
- 95.54% of the companies in the same industry are more expensive than HZNP, based on the Price/Earnings ratio.
- HZNP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
- HZNP is valuated rather expensively with a Price/Forward Earnings ratio of 20.14.
- Based on the Price/Forward Earnings ratio, HZNP is valued cheaply inside the industry as 96.53% of the companies are valued more expensively.
- HZNP's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.54.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 |
4.2 Price Multiples
- HZNP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HZNP is cheaper than 94.88% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.79 | ||
| EV/EBITDA | 27.94 |
4.3 Compensation for Growth
- HZNP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%
5. HZNP Dividend Analysis
5.1 Amount
- No dividends for HZNP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HZNP Fundamentals: All Metrics, Ratios and Statistics
116.3
+0.05 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Revenue(TTM)3.64B
Net Income(TTM)438.00M
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 | ||
| P/S | 7.31 | ||
| P/FCF | 27.79 | ||
| P/OCF | 25.59 | ||
| P/B | 5.01 | ||
| P/tB | 26.53 | ||
| EV/EBITDA | 27.94 |
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROCE | 6.77% | ||
| ROIC | 5.35% | ||
| ROICexc | 7.58% | ||
| ROICexgc | 27.86% | ||
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% | ||
| FCFM | 26.3% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexgc growth 3Y27.62%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Debt/EBITDA | 2.66 | ||
| Cap/Depr | 21.15% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 108.78% | ||
| Profit Quality | 218.81% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 | ||
| Altman-Z | 5.1 |
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%
HORIZON THERAPEUTICS PLC / HZNP Fundamental Analysis FAQ
What is the fundamental rating for HZNP stock?
ChartMill assigns a fundamental rating of 6 / 10 to HZNP.
What is the valuation status for HZNP stock?
ChartMill assigns a valuation rating of 5 / 10 to HORIZON THERAPEUTICS PLC (HZNP). This can be considered as Fairly Valued.
Can you provide the profitability details for HORIZON THERAPEUTICS PLC?
HORIZON THERAPEUTICS PLC (HZNP) has a profitability rating of 8 / 10.
Can you provide the financial health for HZNP stock?
The financial health rating of HORIZON THERAPEUTICS PLC (HZNP) is 7 / 10.